Compare ADMA Biologics Inc (ADMA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Johnson & Johnson — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Johnson & Johnson trades at $265.82 (market cap $643.30B). The key difference: Johnson & Johnson is far larger — about 302× ADMA Biologics Inc's market cap, and Johnson & Johnson pays a 2.01% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | JNJ | |
|---|---|---|
Market Cap | $2.13B | $643.30B |
Sector | Health | Health |
52-Week High | $20.38 | $267.24 |
52-Week Low | $7.60 | $155.17 |
Enterprise Value | $2.20B | $676.24B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
